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ABSTRACT
Background Rhinovirus (RV) infections are the major
precipitant of asthma exacerbations. While neutrophilic
lung inflammation occurs during such infections, its role
remains unclear. Neutrophilic inflammation is associated
with increased asthma severity and steroid refractory
disease. Neutrophils are vital for controlling infections
but also have immunomodulatory functions. Previously,
we found that neutrophils respond to viral mimetics but
not replication competent RV. We aimed to investigate if
neutrophils are activated and/or modulate immune
responses of monocytes during RV16 infection.
Methods Primary human monocytes and autologous
neutrophils were cocultured with or without RV16, in
direct contact or separated by transwells. RV16-
stimulated monocytes were also exposed to lysed
neutrophils, neutrophil membrane components or soluble
neutrophil intracellular components. Interleukin 6 (IL-6)
and C-X-C motif (CXC)L8 mRNA and proteins were
measured by quantitative PCR and ELISA at 24 hours.
Results RV16 induced IL-6 and CXCL8 in monocytes,
but not neutrophils. RV16-induced IL-6 and CXCL8 from
monocytes was reduced in the presence of live
neutrophils. Transwell separation abolished the inhibitory
effects. Lysed neutrophils inhibited RV16-induced IL-6
and CXCL8 from monocytes. Neutrophil intracellular
components alone effectively inhibited RV16-induced
monocyte-derived IL-6 and CXCL8. Neutrophil
intracellular components reduced RV16-induced IL-6 and
CXCL8 mRNA in monocytes.
Conclusions Cell contact between monocytes and
neutrophils is required, and preformed neutrophil
mediator(s) are likely to be involved in the suppression of
cytokine mRNA and protein production. This study
demonstrates a novel regulatory function of neutrophils
on RV-activated monocytes in vitro, challenging the
paradigm that neutrophils are predominantly
proinflammatory.
INTRODUCTION
Neutrophils are the most abundant immune cell in
the circulation and play a vital role in innate
immune responses. These cells are the first line of
defence with the ability to quickly migrate from the
circulation to the site of infection. Neutrophils are
short-lived terminally differentiated cells that
mediate acute anti-microbial functions through the
action of cytotoxic granule proteins and reactive
oxygen species (ROS). They are phagocytic and
take up pathogens into the phagosome where gran-
ules filled with toxic compounds fuse with the
phagosome to eliminate the microbes.1
Degranulation is the other major effector function
where neutrophils exocytose granules from the
cytoplasm. Important neutrophil products include
neutrophil elastase (NE) which cleaves microbial
virulence factors,1 matrix metalloproteinase
(MMP)-9 that digests proteases that degrade NE2
and ROS which damage DNA and essential pro-
teins.3 Improved neutrophil responses are asso-
ciated with enhanced viral clearance4 and less
severe disease.5
It is becoming evident that neutrophils are more
complex than initially thought and have other roles
including in the resolution of inflammation6 and
regulation of the subsequent adaptive immune
response.7 Recently, the interaction between neu-
trophils and the adaptive immune system has
started to be unravelled. For example, interaction
of the programmed death receptor 1 (PD-1) and its
ligand, PD-L1, along with the subsequent release of
ROS from neutrophils inhibited T-cell-derived
interferon-γ (IFN-γ).8 Conversely, activated neutro-
phils can stimulate dendritic cell maturation so that
in turn they stimulate T-cell proliferation.9
Neutrophils are also sources of anti-inflammatory
mediators such as transforming growth factor
(TGF)-β1 and prostaglandins.10
All common respiratory diseases are charac-
terised by periods of stable disease, interspersed by
acute episodes of worsening symptoms known as
Key messages
What is the key question?
▸ If neutrophils are meant to control infections
but do not respond to rhinovirus, then what is
their role during such infections?
What is the bottom line?
▸ Neutrophils are non-responsive to rhinovirus
but modulate immune responses of
proinflammatory monocytes.
Why read on?
▸ In this study, we describe a novel
anti-inflammatory role of neutrophils on
rhinovirus-stimulated monocytes. This changes
how we view neutrophils during infections and
provides valuable insights to their role during
viral-induced asthma exacerbations.
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exacerbations.11 Respiratory viral infections are a major precipi-
tant of exacerbations, with detection rates in exacerbating indi-
viduals of up to 78% in asthma,12 64% in COPD13 and 46% in
cystic fibrosis.14 In particular, rhinoviruses (RV) are the most
common virus type detected during exacerbations.15 The
reasons why viral infections promote exacerbations remain
unclear. In our previous studies, we showed that neutrophils
had functional receptors that detect and respond to viral com-
ponents. However, when challenged with replication competent
RV neutrophils did not respond with increased CXCL8, NE or
MMP-9.16 In contrast, structural airway cells17 18 and mono-
cytes do respond to RV.19
In this study, we characterised the interaction between mono-
cytes, neutrophils and RV. We observed that neutrophils have an
immunomodulatory effect on monocytes and inhibit
RV-induced cytokine release. We describe a novel anti-
inflammatory role for neutrophils when they interact with
RV-stimulated monocytes.
MATERIALS AND METHODS
Volunteer recruitment
The project was approved by the Human Research Ethics
Committee, The University of Sydney prior to commencement
(protocol number: 14813). Volunteers were recruited by
approved flyers placed around The University of Sydney cam-
puses. Participants were required to be over 18 years of age and
be fluent in English. Exclusion criteria included if they were
pregnant, known to faint during venipuncture procedures or
had a bloodborne infection or condition. All patients provided
written informed consent, and basic demographic information
was collected.
Monocyte and neutrophil isolation
Peripheral blood was collected from volunteers, and neutrophils
and monocytes were isolated using a modified standard proto-
col.16 Briefly, whole blood containing acid citrate dextrose as
the anti-coagulant was mixed with 10% dextran (MP
Biomedicals, Santa Ana, California, USA) to allow for red blood
cell sedimentation. The upper layer was removed and overlayed
on Ficoll Paque-PLUS (GE Healthcare, Little Chalfont, UK) and
centrifuged at 490×g for 10 min. The peripheral blood mono-
nuclear cells at the interface of plasma and Ficoll were isolated,
and monocytes were positively selected using magnetic beads
against CD14. From the granulocyte pellet, neutrophils were
positively selected using magnetic beads against CD16. Further
details are provided in the online supplement. Typical purity of
both cell types were 99% or greater.
RV16
RV16 was generously donated by Professor Sebastian Johnston,
Imperial College, London. RV16 was grown in HeLa cells by
standard procedures.20 RV16 was purified from viral stocks gen-
erated from HeLa cells by polyethylene glycol precipitation and
filtration through a 100 000 molecular weight filter.21
Infectivity titres were determined by a titration assay.20 Purified
RV16 was used in all experiments.
Neutrophil and monocyte coculture
Neutrophils and monocytes were resuspended in 1% fetal
bovine serum (Glendarach Biologicals, Melbourne, Australia),
1% 1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) (Gibco) and 1% penicillin/streptomycin roswell park
memorial institute (RPMI) 1640 (Gibco). 0.5×106 neutrophils
and 0.5×106 of autologous monocytes were cultured separately
and together at a 1:1 ratio in 24-well plates. They were cultured
in media alone (control) and in the presence of RV16 at a multi-
plicity of infection (MOI) of 1 infectious particle per cell as pre-
viously published.22 Cells were incubated at 37°C with 5% CO2
for 24 hours and cell-free supernatant was collected and stored
at −80°C for analysis.
Neutrophil and monocyte coculture with transwell
separation
Neutrophils were placed into transwell inserts while autologous
monocytes were placed into the well below. The coculture
system was modified with 0.4 or 3 μm pore size polyethylene
terephthalate (PET) transwell inserts (Corning, Corning, New
York, USA). RV16 (MOI1) was placed into the lower chamber at
time of cell seeding and cultured at 37°C with 5% CO2 for
24 hours and pooled (upper and lower chamber) cell-free super-
natant was collected and stored at −80°C for analysis.
To confirm that neutrophils were able to migrate through the
3 μm pore size PET transwell inserts, neutrophils were placed
into the upper chamber. Previously collected cell-free superna-
tants from RV-stimulated monocytes were placed in the lower
chamber. Neutrophils were cultured for 1 hour at 37°C with
5% CO2. Manual cell counts were performed on neutrophils
that had migrated into the lower chamber.
Effects of lysed neutrophils and neutrophil components on
monocytes
The same direct coculture system was set up; however, live neu-
trophils were replaced with lysed cells. Neutrophils at the same
concentration were frozen at −80°C for 15 min and then
thawed at rapidly at 37°C before being resuspended and placed
with autologous monocytes with the same protocol in the pres-
ence and absence of RV16 (MOI1).
Alternatively, the thawed solution was spun in an Eppendorf
centrifuge at 16.2×g for 10 min to pellet the membranes. The
supernatant was collected, and the intracellular components of
0.5×106 lysed neutrophils were applied to autologous mono-
cytes with or without RV16 (MOI1). The pellet was washed
three times with media and centrifuged for 5 min after each
wash. The pellet was resuspended, and the membrane fragments
were added to separate monocyte cultures with or without
RV16.
For heat inactivation, the intracellular components were
heated to 95°C for 10 min and then cooled for 5 min at 4°C
before applying to monocyte cultures with or without RV16
(MOI1).
All cultures were incubated at 37°C with 5% CO2 for
24 hours, and cell-free supernatant was collected and stored at
−80°C for analysis.
Investigation of immune suppressive role of TGF-β1
Neutralising antibodies specific for TGF-β1 (R&D Systems,
Minneapolis, Minnesota, USA) were added to either monocytes
alone or coculture of monocytes and neutrophils at a final con-
centration of 10 μg/mL as previously described.23 The cultures
were incubated at 37°C with 5% CO2 for 24 hours, and cell-free
supernatant was collected and stored at −80°C for analysis.
Neutralising antibodies specific for TGF-β1 were confirmed to
effectively neutralise recombinant TGF-β1 (see online supple-
mentary figure S1).
Recombinant TGF-β1 (R&D Systems) was added to mono-
cytes alone at 4 and 20 μg/mL and incubated at 37°C with 5%
CO2 for 24 hours, and cell-free supernatant was collected and
stored at −80°C for analysis.
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Effect of indomethacin treatment on monocytes
Neutrophils, monocytes and the combination of neutrophils and
monocytes were pretreated with 10−6 M indomethacin (Sigma
Aldrich) as previously published,24 dimethyl sulfoxide (DMSO)
(Sigma Aldrich) as a vehicle control or no treatment (control)
for 30 min at room temperature. Cells were then incubated at
37°C with 5% CO2 for 24 hours in the presence or absence of
RV16 (MOI1). Cell-free supernatant was collected and stored at
−80°C for analysis. 10−6 M indomethacin was confirmed to be
an effective concentration to prevent PGE2 synthesis (see online
supplementary figure S2).
Effect of H2O2 on monocytes
Monocytes were treated with increasing concentrations of H2O2
(0.0125 nM, 0.125 nM, 0.25 nM and 100 mM) (Sigma
Aldrich). Monocytes with no treatment and monocytes cocul-
tured with neutrophils were used as controls. Cells were treated
for 24 hours at 37°C with 5% CO2. Cell-free supernatant was
collected and stored at −80°C for analysis.
Effect of neutralising PD-1 on monocytes
Neutrophils, monocytes and the combination of neutrophils and
monocytes were pretreated with 10 μg/mL of neutralising PD-1
antibodies as previously described25 or isotype control
(BioLegend, San Diego, California, USA) at 37°C for 1 hour.
Cells were then either stimulated with RV16 (MOI1) or left
unstimulated and incubated at 37°C with 5% CO2 for 24 hours.
Cell-free supernatant was collected and stored at −80°C for
analysis.
Quantitative PCR
Interleukin 6 (IL-6), CXCL8, IFN-α, IFN-β, IL-28, IL-29A,
TNF-α and vascular endothelial growth factor (VEGF) mRNA
expression in monocytes were detected using quantitative PCR
(qPCR). Total cellular RNA was isolated using the NucleoSpin
RNA kit (Macherey-Nagel, Düren, Germany) according to the
manufacturer’s instructions. RNA was converted to cDNA
(Invitrogen, Carlsbad, California, USA), and qPCR was carried
out on cDNA using the StepOne Real-Time PCR system
(Applied Biosystems, Carlsbad, California, USA) using Taqman
Gene Expression Assays (Applied Biosystems). Further details
can be found in the online supplement.
ELISAs
IL-6, CXCL8 and TGF-β1 production was measured using a
sandwich ELISA in duplicate. Specific ELISA kits from R&D
Systems (Minneapolis, Minnesota, USA) were used according to
the manufacturer’s instructions. Detection limits were
15.6 pg/mL for IL-6 and 31.2 pg/mL for CXCL8 and TGF-β1.
Statistical analysis
Data are presented as the mean±SEM. Data were assumed to be
non-parametric due to small sample sizes. A non-parametric
Wilcoxon paired t-test or a non-parametric paired one-way ana-
lysis of variance with Dunn’s multiple comparison test was per-
formed. Significant changes were identified where (p<0.05).
RESULTS
Monocytes but not neutrophils are stimulated to produce
cytokines by RV16
We first assessed the production of cytokines by neutrophils and
monocytes exposed to RV16 at a range of MOIs (0.5–5) and
found that an MOI1 was the lowest concentration to illicit a
response (see online supplementary figure S3). Monocytes had a
robust response to RV16 exposure with the induction of both
IL-6 and CXCL8 release (figure 1A, B). In contrast, neutrophil
IL-6 release was below the detection limit of the assay both
basally and with RV16 stimulation. Interestingly, neutrophil
CXCL8 basal release was low (244 pg/mL) and was not induced
in the presence of RV16 (figure 1C).
Coculture of monocytes with neutrophils and RV16 exposure
results in cell contact-mediated inhibition of cytokine
release
As neutrophils did not respond to RV16, we investigated
whether monocytes activated with the virus interacted with neu-
trophils in coculture. Remarkably, monocyte-derived
RV16-induced IL-6 and CXCL8 was reduced by ∼50%–70% in
the presence of neutrophils (figure 2A, B).
The interaction between cocultured monocytes and neutro-
phils may involve contact between the two cell types and/or the
release of soluble factors. To assess these possibilities, we modi-
fied the coculture model. Monocytes were separated from neu-
trophils with 0.4 μm transwells where cells were unable to pass
through the membranes but soluble mediators were freely able
to diffuse. Prevention of cell-to-cell contact resulted in the loss
of neutrophil inhibitory effects on monocyte cytokine release
(figure 2C, D).
We also increased the transwell pore size to 3 μm to allow
neutrophils in the upper chamber to migrate towards monocytes
in the lower chamber in an attempt to restore the inhibitory
response. We initially confirmed that neutrophils migrated
through the transwell towards the supernatant from
RV16-stimulated monocytes over the course of 1 hour (control:
50×104 cells/mL, RV-stimulated monocyte supernatant:
127×104 cells/mL, data not shown). However, over the course
of 24 hours the inhibitory effects on CXCL8 release were
unable to be rescued when neutrophils were allowed to migrate
towards monocytes but were slightly restored with IL-6 release
(figure 2E, F).
PD-1 does not appear to mediate inhibition of
monocyte-derived cytokine release
We then investigated the mechanisms of cell contact-mediated
inhibition of cytokine release. Since de Kleijn et al8 found that
PD-1/PD-L1 ligation had anti-inflammatory effects in T cells, we
investigated if PD-1/PD-L1 was responsible for neutrophil inhib-
ition of virus-activated monocytes. There was no difference in
cytokine release in the presence or absence of the anti-PD-1
antibody (figure 3A, B). Thus, the ligation of these cell surface
proteins does not appear to be essential for neutrophil inhib-
ition of monocyte-derived cytokines.
A constitutively produced neutrophil factor inhibits
RV16-induced monocyte-derived cytokine release by
reducing monocyte mRNA levels
As inhibition of RV16-induced monocyte cytokine release was
through cell contact, we investigated if neutrophils constitutively
modulated the immune response or if de novo protein was
required. We treated autologous monocytes with lysed neutro-
phils (the same concentration as previous experiments). Lysed
neutrophils inhibited RV-induced IL-6 and CXCL8 release to the
same degree as in the whole cell coculture model (figure 4A, B).
We then expanded this analysis by separating the lysed neutro-
phil solution into the membranous and soluble intracellular com-
ponents to elucidate if inhibition was mediated by membrane
bound or intracellular factors. The intracellular component
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effectively inhibited RV16-induced monocyte IL-6 and CXCL8.
While the membrane component caused a 60%–70% reduction
in IL-6, it was not statistically significant (figure 4C). The mem-
brane component did not inhibit RV-induced CXCL8 release
from monocytes (figure 4D). As the neutrophil intracellular com-
ponent consistently inhibited RV-induced IL-6 and CXCL8 from
monocytes, subsequent experiments focused on the inhibitory
effects of the neutrophil intracellular component.
We then examined whether the effects occur at the gene tran-
scription level. We assessed cytokine mRNA levels in monocytes
treated with neutrophil intracellular components and stimulated
with RV16. We found that IL-6, CXCL8 and TNF-α mRNA
were downregulated following exposure to neutrophil intracel-
lular components while IFNα and IFNβ were not altered
(figure 5A–E). IL-28, IL-29A and VEGF mRNA were not
detected.
TGF-β1 is unlikely responsible for neutrophil inhibitory
effects
TGF-β1 has known anti-inflammatory effects and was present in
supernatants from cocultured monocytes and neutrophils (figure
6A, B). However, RV16 did not induce TGF-β1 from neutro-
phils (figure 6C) or monocytes (figure 6D). To investigate the
role of TGF-β1 further, we examined the effect of neutralising
antibodies in the coculture model. Depletion of TGF-β1 did not
affect the inhibition of IL-6 or CXCL8 production from
RV-activated monocytes by neutrophils (figure 6E, F).
Furthermore, addition of recombinant TGF-β1 (4 and
20 ng/mL) reduced IL-6 release by 50% (not statistically signifi-
cant) compared with monocytes alone but was not as effective
as neutrophils cultured with monocytes (figure 6G). However, it
did not prevent the inhibition of CXCL8 release (figure 6H).
Neutrophil soluble factor is heat resistant and is unlikely to
be a prostaglandin or H2O2
It is unlikely that TGF-β1 is the soluble neutrophil factor
responsible for inhibiting RV-activated monocytes as it appeared
to trend towards a decrease in IL-6 but not CXCL8. We then
further characterised the neutrophil intracellular component in
attempts to identify the molecule responsible. As most proteins
can be denatured by heat, and hence lose activity, we investi-
gated if the inhibitory factor is heat labile. Heating did not
abolish the inhibitory effects of the intracellular neutrophil com-
ponents on IL-6 or CXCL8 release (figure 7A, B).
Since, it appears that a protein is not the unknown inhibitory
factor isolated from neutrophils, we next examined the potential
for it to be a lipid mediator, such as prostaglandins, as they can
have anti-inflammatory functions.26 We treated RV-activated
monocytes and neutrophils in coculture with the cyclooxygen-
ase (COX) inhibitor, indomethacin (figure 7C, D). We found no
difference with treatment, indicating that prostaglandins or
other lipid mediators are unlikely to be involved.
Previously, Pillay et al27 have described a role for neutrophil-
derived H2O2 in inhibiting T-cell proliferation. We next
explored the possibility for neutrophil-derived H2O2 to be the
inhibitory factor in our model by adding it into monocyte cul-
tures. As expected, the coculture of monocytes with neutrophils
had around a 75% decrease in IL-6 and CXCL8 release com-
pared with monocytes alone. The addition of H2O2 to mono-
cytes alone resulted in no change in IL-6 release but a
dose-dependent increase in CXCL8 (figure 7E, F). However, we
were unable to detect H2O2 in the supernatants from neutro-
phils and monocytes stimulated with RV16 nor the coculture of
the two cell types using a fluorescence assay kit (Cayman
Chemicals, Ann Arbor, Michigan, USA).
DISCUSSION
To our knowledge, this is the first study to observe an immuno-
modulatory function of neutrophils on monocyte function in
the context of an RV infection. We found that neutrophils are
unable to respond directly to RV16 with cytokine release but
monocytes are stimulated to release large amounts of IL-6 and
CXCL8 by the virus. Neutrophils appear to be non-responsive
to RV16 but actually reduce cytokine release from activated
monocytes in a cell contact-dependent manner that is unlikely
to be PD-1/PD-L1 dependent. A soluble factor that is constitu-
tively produced in neutrophils is responsible; this soluble factor
(s) reduces cytokine mRNA production and in turn protein pro-
duction in monocytes. We have deduced that this unknown neu-
trophil factor resides internally, is resistant to heat and is
unlikely to be TGF-β1, a lipid mediator such as prostaglandins
or H2O2.
Neutrophils are thought to be a homogenous population of
effector, proinflammatory cells. They are known to migrate
swiftly to sites of infection to contain the spread of the
Figure 1 RV16 induced cytokine
release from human peripheral blood
monocytes but not from peripheral
blood neutrophils. (A) IL-6 and (B)
CXCL8 release from human peripheral
blood monocytes, stimulated with RV16
(multiplicity of infection of 1 (MOI1))
for 24 hours (n=14). (C) CXCL8 release
from human peripheral blood
neutrophils, stimulated with RV16
(MOI1) for 24 hours (n=10). IL-6
release from neutrophils was below the
limit of detection and is not shown.
Data are presented as mean±SEM.
***p<0.001. IL, interleukin;
RV, rhinovirus.
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Figure 2 Cytokine release from human peripheral blood monocytes in coculture with autologous neutrophils is altered by cell contact. (A) IL-6 and
(B) CXCL8 release from monocytes cocultured with neutrophils, or separated by cell impervious (C and D) or cell porous (E and F) transwells and
stimulated with RV16 (multiplicity of infection of 1) (n=5–10). Data are presented as mean±SEM. *p<0.05, **p<0.01 between indicated groups. IL,
interleukin; RV, rhinovirus.
Figure 3 The effect of programmed death receptor 1 (PD-1) inhibition on cytokine release from human peripheral blood monocytes. (A) IL-6 and
(B) CXCL8 release from monocytes cultured alone or with neutrophils with isotype control antibodies or with αPD-1 neutralising antibodies and
stimulated with RV16 (multiplicity of infection of 1) (n=3). Data are presented as mean±SEM. *p<0.05. IL, interleukin; RV, rhinovirus.
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pathogen. We know that neutrophils migrate to the airways
during a respiratory viral infection28 and that improved neutro-
phil responses help control infections4 and limit the develop-
ment of severe disease.5 Neutrophilia occurs in stable asthmatic
patients 29 and in patients with COPD,30 and in experimental
asthma and COPD neutrophilia is associated with more severe,
steroid-insensitive disease.31–33 However, the role of the neutro-
phil in clearing RV is not clear despite their influx and this
raises the question of their purpose during such infections.
Further clinical and experimental studies using appropriate
models are required to fully elucidate their roles.34 35
Our previous work has shown that despite neutrophils
expressing functional innate immune receptors for detecting RV,
they are non-responsive to live RV16.16 Neutrophil activation
appears to be due to inflammatory mediators generated from
other cells.36 We know that the primary site of RV infection is
the epithelium37 38 and these cells could be the source of media-
tors that activate neutrophils. However, our preliminary work
suggested otherwise. We applied RV16-infected BEAS-2B super-
natants onto neutrophils. We also cocultured neutrophils with
RV16-infected primary bronchial epithelial cells. In both cases,
we found that neutrophils were not activated. This led us to
suspect that perhaps another immune cell capable of detecting
the presence of RV16 could in turn activate neutrophils.
Monocytes are bone marrow-derived cells that are predomin-
ately found in the circulation. They can differentiate into den-
dritic cells and a variety of tissue specific macrophages, and
mediate host defence. Like most leucocytes, monocytes migrate
to the airways in response to signals from the epithelium,39
through adhesion to the endothelium, tethering and
extravasation following a chemotactic gradient, usually CCL2
monocyte chemoattractive protein 1 (MCP1).40
Interestingly, our preliminary work showed that monocytes
produce approximately 10 times more CXCL8 in response to
RV16 compared with lipopolysaccharide (LPS)-stimulated neu-
trophils. CXCL8 is a potent neutrophil chemoattractant, and
monocytes are a significant source of this chemokine. The new
immunomodulatory functions of neutrophils that we have iden-
tified in this study may be a feedback mechanism to control
these monocyte-driven inflammatory responses, which when
excessive may be tissue damaging. While our study focused on
the mechanism of inhibition, future studies looking at whether
there is dysfunction in this mechanism in asthmatic, COPD or
cystic fibrosis (CF) neutrophils will be of substantial interest and
may potentially be manipulated for therapeutic benefit. In add-
ition, as monocytes have the potential to differentiate into
macrophages and dendritic cells, it would also be important to
investigate if neutrophils also have immunomodulatory effects
on these cells.
TGF-β1 was detected in our coculture supernatants and has
known anti-inflammatory effects,41 however, was not induced
by RV16. Nevertheless, antibody neutralisation in the coculture
model along with the addition of TGF-β1 to monocytes alone
at concentrations greater than we measured in our coculture
supernatants excluded this cytokine from being the soluble
factor we were searching for.
We also assessed the potential role of PD-1/PD-L1 and H2O2
to be involved in this mechanism as previous reports have impli-
cated these factors in suppressing T-cell activity.8 27 Our data
are limited in that we were unable to provide positive controls
Figure 4 Cytokine release from human peripheral blood monocytes cultured with autologous lysed neutrophils or components of neutrophils. (A)
IL-6 and (B) CXCL8 release from monocytes cocultured with lysed neutrophils or intracellular and membrane components of neutrophils (C and D)
and stimulated with RV16 (multiplicity of infection of 1). Data are presented as mean±SEM. (n=8–10). *p<0.05, **p<0.01, ***p<0.001 between
indicated groups. IL, interleukin; RV, rhinovirus.
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in our PD-1/PD-L1 experiments. However, our data suggest
that it is unlikely that PD-1/PD-L1 is involved but further inves-
tigation is required. In addition, we only investigated the effect
of H2O2 on monocyte cultures and not on the coculture model.
Nevertheless, we conclude that exogenous H2O2 appears to
have no effect on RV-induced cytokine release from monocytes
and therefore is also unlikely to be the mediator in question.
There remains the potential that a different receptor(s) is/are
engaged and different neutrophil mediator(s) is/are involved
which requires further investigation.
It is becoming clear that the pool of neutrophils is a heteroge-
neous population. Pillay et al27 described three distinct popula-
tions of neutrophils in the circulation after intravenous LPS
administration in humans. Neutrophils with single banded
nuclei which were likely immature cells released from the
bone marrow in response to the stimulus, mature neutrophils
with typical segmented nuclei and a third group with
hypersegmented nuclei which they found to hold immunomo-
dulatory functions. Interestingly, these suppressor neutrophils
and mature neutrophils were CD16high. Our protocol used
CD16 magnetic beads to purify the neutrophil samples by posi-
tive selection. We may have preferentially selected out CD16high
suppressor neutrophils unintentionally during purification from
the granulocyte fraction; however, a more detailed investigation
of different populations of suppressor neutrophils is outside the
scope of this study.
It is evident that neutrophil functions have been oversimpli-
fied in the past. It is now clear that they bridge the gap between
the innate and adaptive immune system by cross-talking with
dendritic cells, B cells and T cells and modulating their
responses.42 43 Most of the functions of suppressor neutrophils
have been described using murine models; however, the few
studies conducted in humans align closely with our proposed
mechanism. In line with other studies, we found that there is a
Figure 5 Cytokine mRNA expression in human peripheral blood monocytes cultured with isolated autologous neutrophil intracellular components.
(A) IL-6, (B) CXCL8, (C) IFN-α, (D) IFN-β and (E) TNF-α monocyte mRNA after RV16 (multiplicity of infection of 1) stimulation represented as fold
change of unstimulated control (n=5–7). Data are presented as mean±SEM. *p<0.05. IL, interleukin; RV, rhinovirus.
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requirement for cell contact, or a formation of an immuno-
logical synapse between the two cell types for inhibition to
occur.8 9 27 However, our experiments suggest that PD-1 and
PD-L1 were not involved. Similarly, roles for a secreted mol-
ecule into the synapse have been identified, arginase-1 in mice44
and H2O2
42 in human T-cell models; however, our data suggest
that H2O2 is unlikely involved in this mechanism we describe.
This study has limitations as it is an ex vivo model which may
not accurately reflect physiological conditions. This model uses
1:1 ratios of neutrophils to monocytes which is possible to
occur in vivo during inflammation when both cell types are
recruited into the airways; however, it is possible that there may
be more monocytes to neutrophils or vice versa. There is also
evidence that there are subtypes of neutrophils27 and
Figure 6 The effect of transforming growth factor (TGF)-β1 on cytokine release from human peripheral blood monocyte and neutrophil cocultures.
(A) TGF-β1 release from monocytes alone and cocultured with neutrophils in the absence of RV16 and (B) in the presence of RV16 (multiplicity of
infection of 1 (MOI1)) (n=6–7). (C) TGF-β1 release from neutrophils and (D) monocytes stimulated with RV16 (MOI1) (n=5–6). (E) IL-6 and (F)
CXCL8 release from monocytes and neutrophil cocultures in the presence of anti-TGF-β1 neutralising antibodies and stimulated with RV16 (MOI1)
(n=4). (G) IL-6 and (H) CXCL8 release from monocytes stimulated with recombinant human TGF-β1 (n=6). Data are presented as mean±SEM.
*p<0.05, **p<0.01. IL, interleukin; RV, rhinovirus.
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monocytes45 which we did not characterise in this study. Future
studies investigating the proportion and roles of various sub-
types of neutrophils and monocytes, particularly suppressor sub-
types, would be of interest.
In this study, we routinely used the control conditions of
RV-stimulated monocytes alone and cocultured with neutrophils.
Despite keeping the protocol consistent between experiments,
there are fluctuations in the amounts of IL-6 (10 000–
100 000 pg/mL) and CXCL8 (100 000–300 000 pg/mL) induced
from monocytes cultured alone. This also occurred with the
coculture of monocytes with neutrophils. We suspect the
variability is most likely due to the heterogeneity of responses
observed when using primary human cells.
We investigated if nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) was dysregulated in monocytes
treated with neutrophil products, but found no evidence of
NF-κB activation following RV exposure of monocytes (data not
shown). From our previous work in airway smooth muscle cells,
RV induced IL-6 in an NF-κB dependent pathway.17 This was
replication independent, and likely triggered by RV engagement
with intracellular adhesion molecule (ICAM)-1. However, in
monocytes, RV-induced IL-6 and CXCL8 may occur following
Figure 7 The effect of neutrophil-related factors on cytokine release from human peripheral blood monocyte and neutrophil cocultures. (A) IL-6
and (B) CXCL8 release from monocytes cultured with autologous heat-inactivated neutrophil intracellular components and in the presence of RV16
(multiplicity of infection of 1 (MOI1)) (n=9). (C) IL-6 and (D) CXCL8 release from monocytes and monocytes cocultured with neutrophils in either
media alone, DMSO vehicle control or indomethacin or (E and F) in the presence of H2O2 and stimulated with RV16 (MOI1) (n=3–4). Data are
presented as mean±SEM. *p<0.05, **p<0.01, ***p<0.001. IL, interleukin; RV, rhinovirus.
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viral detection, as RV does not replicate in monocytes46 but RV
RNA can be isolated in the monocytes following RV exposure.
Therefore, viral recognition through toll like receptor (TLR)3, 7
and/or 8 is likely to occur. Activation of these pathways leading
to cytokine production is known to be NF-κB independent.
Alternatively, RV-induced cytokine release may differ from other
cell types, and still be NF-κB independent even if viral replica-
tion occurs within these cells. The lack of NF-κB activation may
be beneficial in these cases as it may be detrimental to overly
activate cytokine responses (in the worst case leading to a cyto-
kine storm) each time a person suffers from a cold.
In this study, we could not identify the specific inhibitory
mechanism involved. We speculate that it could potentially be
microRNAs or long intervening non-coding RNAs that may be
responsible. MicroRNAs have recently been shown to alter
macrophage function,47 and a number have been identified to
modulate immune responses and some have been associated
with respiratory disease.48
Our research challenges the notion that neutrophils are
responsible for aberrant inflammation found during RV infec-
tions in asthmatics which results in acute symptoms. We
propose that potentially the immunomodulatory functions of
neutrophils from asthmatics may be dysfunctional or that mono-
cytes contribute more to the inflammatory environment in these
patients than neutrophils. While it is speculation, we believe
that it is an important area that future research needs to address.
Author affiliations
1Woolcock Institute of Medical Research, The University of Sydney, Sydney, New
South Wales, Australia
2Discipline of Pharmacology, Faculty of Medicine, School of Medical Sciences, The
University of Sydney, Sydney, New South Wales, Australia
3Priority Research Centre for Asthma and Respiratory Disease, The University of
Newcastle, Newcastle, New South Wales, Australia
4Department of Pathology and Medical Biology, University of Groningen, University
Medical Centre Groningen, Groningen, Netherlands
5Woolcock Emphysema Centre, Woolcock Institute of Medical Research, The
University of Sydney, Sydney, New South Wales, Australia
6Faculty of Science, School of Life Sciences, University of Technology Sydney, Sydney,
New South Wales, Australia
7Centre for Health Technologies and Molecular Biosciences, School of Life Sciences,
University of Technology Sydney, Sydney, New South Wales, Australia
Contributors FSMT, PMH, AJA, JKB, KJB and BGO provided conception and
design of the study. FSMT carried out recruitment, completed all cell biology,
laboratory work and data analysis. All authors contributed to the preparation of the
manuscript.
Funding This study was funded by the National Health and Medical Research
Council (NHMRC), Australia. PMH was supported by an NHMRC Principal Research
Fellowship, JKB and BGO were supported by NHMRC Career Development
Fellowships #1032695 and #1026880.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Human Research Ethics Committee, The University of Sydney.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Amulic B, Cazalet C, Hayes GL, et al. Neutrophil Function: From Mechanisms to
Disease. Annu Rev Immunol 2012;30:459–89.
2 Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of
inflammation and innate immunity. Nat Rev Immunol 2004;4:617–29.
3 Fang FC. Antimicrobial reactive oxygen and nitrogen species: Concepts and
controversies. Nat Rev Microbiol 2004;2: 820–32.
4 Chen-Yu Hsu A, Starkey MR, Hanish I, et al. Targeting PI3K-p110α suppresses
influenza virus infection in chronic obstructive pulmonary disease. Am J Resp Crit
Care 2015;191:1012–23.
5 Tate MD, Deng YM, Jones JE, et al. Neutrophils ameliorate lung injury and the
development of severe disease during influenza infection. J Immunol
2009;183:7441–50.
6 Kennedy AD, DeLeo FR. Neutrophil apoptosis and the resolution of infection.
Immunol Res 2009;43:25–61.
7 Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation
and regulation of innate and adaptive immunity. Nat Rev Immunol
2011;11:519–31.
8 de Kleijn S, Langereis JD, Leentjens J, et al. IFN-γ-Stimulated Neutrophils
Suppress Lymphocyte Proliferation through Expression of PD-L1. PLoS ONE 2013;8:
e72249.
9 van Gisbergen KPJM, Sanchez-Hernandez M, Geijtenbeek TBH, et al.
Neutrophils mediate immune modulation of dendritic cells through
glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med
2005;201:1281–92.
10 Wright HL, Moots RJ, Bucknall RC, et al. Neutrophil function in inflammation and
inflammatory diseases. Rheumatology (Oxford) 2010;49:1618–31.
11 Hsu AC, See HV, Hansbro PM, et al. Innate immunity to influenza in chronic airways
diseases. Respirology 2012;17:1166–75.
12 Grissell TV, Powell H, Shafren DR, et al. Interleukin-10 gene expression in acute
virus-induced asthma. Am J Resp Crit Care 2005;172:433–9.
13 Tan WC, Xiang X, Qiu D, et al. Epidemiology of respiratory viruses in patients
hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic
obstructive pulmonary disease. Am J Med 2003;115:272–7.
14 Wat D, Gelder C, Hibbitts S, et al. The role of respiratory viruses in cystic fibrosis.
J Cyst Fibros 2008;7:320–8.
15 Hershenson MB. Rhinovirus-Induced Exacerbations of Asthma and COPD. Scientifica
(Cairo) 2013;2013:405876.
16 Tang FSM, Van Ly D, Spann K, et al. Differential neutrophil activation in viral
infections: Enhanced TLR-7/8-mediated CXCL8 release in asthma. Respirology
2016;21:172–9.
17 Oliver B, Johnston S, Baraket M, et al. Increased proinflammatory responses from
asthmatic human airway smooth muscle cells in response to rhinovirus infection.
Resp Res 2006;7:71.
18 Van Ly D, King NJC, Moir LM, et al. Effects of β(2) Agonists, Corticosteroids, and
Novel Therapies on Rhinovirus-Induced Cytokine Release and Rhinovirus Replication
in Primary Airway Fibroblasts. J Allergy (Cairo) 2011;2011:457169.
19 Korpi-Steiner NL, Bates ME, Lee WM, et al. Human rhinovirus induces robust IP-10
release by monocytic cells, which is independent of viral replication but linked to
type I interferon receptor ligation and STAT1 activation. J Leukoc Biol
2006;80:1364–74.
20 Papi A, Johnston SL. Rhinovirus Infection Induces Expression of Its Own Receptor
Intercellular Adhesion Molecule 1 (ICAM-1) via Increased NF-kappaB-mediated
Transcription. J Biol Chem 1999;274:9707–20.
21 Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus-induced
disease and exacerbation of allergic airway inflammation. Nat Med
2008;14:199–204.
22 Van Ly D, De Pedro M, James P, et al. Inhibition of phosphodiesterase 4 modulates
cytokine induction from toll like receptor activated, but not rhinovirus infected,
primary human airway smooth muscle. Resp Res 2013;14:127.
23 Cho ML, Min SY, Chang SH, et al. Transforming growth factor beta 1(TGF-beta1)
down-regulates TNFalpha-induced RANTES production in rheumatoid synovial
fibroblasts through NF-kappaB-mediated transcriptional repression. Immunol Lett
2006;105:159–66.
24 Elliott GR, Lauwen APM, Bonta IL. Prostaglandin E2 inhibits and indomethacin and
aspirin enhance, A23187-stimulated leukotriene B4 synthesis by rat peritoneal
macrophages. Brit J Pharmacol 1989;96:265–70.
25 Velu V, Kannanganat S, Ibegbu C, et al. Elevated expression levels of
inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific
CD8 T cells during chronic infection but not after vaccination. J Virol
2007;81:5819–28.
26 Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins. J Invest
Med 2009;57:703–8.
27 Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic
inflammation inhibits T cell responses through Mac-1. J Clin Invest
2012;122:327–36.
28 Nagarkar DR, Wang Q, Shim J, et al. CXCR2 is required for neutrophilic airway
inflammation and hyperresponsiveness in a mouse model of human rhinovirus
infection. J Immunol 2009;183:6698–707.
29 Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic
asthma and bronchiectasis. Thorax 2007;62:211–18.
30 Pesci A, Majori M, Cuomo A, et al. Neutrophils infiltrating bronchial epithelium in
chronic obstructive pulmonary disease. Resp Med 1998;92:863–70.
31 Wang W, Li JJ, Foster PS, et al. Potential therapeutic targets for steroid-resistant
asthma. Curr Drug Targets 2010;11: 957–70.
1048 Tang FSM, et al. Thorax 2016;71:1039–1049. doi:10.1136/thoraxjnl-2015-207781
Respiratory infection
32 Beckett EL, Stevens RL, Jarnicki AG, et al. A new short-term model of chronic
obstructive pulmonary disease identifies a role for mast cell tryptase in
pathogenesis. J Allergy Clin Immunol 2013;131: 752–62.
33 Essilfie AT, Horvat JC, Kim RY, et al. Macrolide therapy suppresses key features of
experimental steroid-sensitive and steroid-insensitive asthma. Thorax
2015;70:458–67.
34 Rohde G, Message SD, Haas JJ, et al. CXC chemokines and antimicrobial peptides
in rhinovirus-induced experimental asthma exacerbations. Clin Exp Allergy
2014;44:930–9.
35 Starkey MR, Jarnicki AG, Essilfie AT, et al. Murine models of infectious
exacerbations of airway inflammation. Curr Opin Pharmacol 2013;13:337–44.
36 Bataki EL, Evans GS, Everard ML. Respiratory syncytial virus and neutrophil
activation. Clin Exp Immunol 2005;140:470–7.
37 Arruda E, Boyle TR, Winther B, et al. Localization of Human Rhinovirus Replication
in the Upper Respiratory Tract by in situ Hybridization. J Infect Dis
1995;171:1329–33.
38 Bardin PG, Johnston SL, Sanderson G, et al. Detection of rhinovirus infection of the
nasal mucosa by oligonucleotide in situ hybridization. Am J Respir Cell Mol Biol
1994;10:207–13.
39 Hallstrand TS, Hackett TL, Altemeier WA, et al. Airway epithelial regulation of
pulmonary immune homeostasis and inflammation. Clin Immunol 2014;151:1–15.
40 Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev
Immunol 2011;11:762–74.
41 Sanjabi S, Zenewicz LA, Kamanaka M, et al. Anti-inflammatory and
pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and
autoimmunity. Curr Opin Pharmacol 2009;9:447–53.
42 Pillay J, Tak T, Kamp VM, et al. Immune suppression by neutrophils and
granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol
Life Sci 2013;70:3813–27.
43 Mócsai A. Diverse novel functions of neutrophils in immunity, inflammation, and
beyond. J Exp Med 2013;210:1283–99.
44 Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor
cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–
dependent mechanism that is up-regulated by interleukin-13. Blood
2010;116:5738–47.
45 Gordon S, Plüddemann A, Martinez Estrada F. Macrophage heterogeneity in tissues:
phenotypic diversity and functions. Immunol Rev 2014;262:36–55.
46 Gern JE, Dick EC, Lee WM, et al. Rhinovirus enters but does not replicate inside
monocytes and airway macrophages. J Immunol 1996;156:621–7.
47 Tay HL, Kaiko GE, Plank M, et al. Antagonism of miR-328 Increases the
Antimicrobial Function of Macrophages and Neutrophils and Rapid Clearance of
Non-typeable Haemophilus Influenzae (NTHi) from Infected Lung. PLoS Pathog
2015;11:e1004549.
48 Foster PS, Plank M, Collison A, et al. The emerging role of microRNAs in
regulating immune and inflammatory responses in the lung. Immunol Rev
2013;253:198–215.
Tang FSM, et al. Thorax 2016;71:1039–1049. doi:10.1136/thoraxjnl-2015-207781 1049
Respiratory infection
